ArticleInternational journal of general medicine2026
Association of the Remnant Cholesterol Inflammatory Index with Acute Kidney Injury After Primary Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction: A Retrospective Observational Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Contrast-induced acute kidney injury (CI-AKI) remains a clinically important complication after percutaneous coronary intervention (PCI), particularly in patients with ST-segment elevation myocardial infarction (STEMI). The remnant cholesterol inflammatory index (RCII), integrating remnant cholesterol (RC) and C-reactive protein (CRP), may reflect both residual lipid burden and systemic inflammatory activation. This study aimed to evaluate the association between RCII and CI-AKI in patients with STEMI undergoing PCI. Methods: This single-center retrospective observational study included 771 consecutive patients with STEMI who underwent primary PCI between May 2023 and May 2026. The primary outcome was in-hospital CI-AKI. Multivariable logistic regression, restricted cubic spline (RCS) analysis, receiver operating characteristic (ROC) analysis, integrated discrimination improvement (IDI), and continuous net reclassification improvement (NRI) were performed. Results: CI-AKI occurred in 85 patients (11.0%). Patients with high RCII had a significantly higher incidence of CI-AKI than those with low RCII (15.32% vs 6.74%, P<0.001). In multivariable logistic regression analysis, RCII remained independently associated with CI-AKI after adjustment for relevant covariates (adjusted odds ratio=1.026, 95% confidence interval: 1.007-1.045, P=0.007). RCS analysis demonstrated a significant nonlinear dose-response relationship between RCII and CI-AKI. The addition of RCII to the baseline clinical model resulted in significant improvements in IDI (0.027, P=0.015) and continuous NRI (0.283, P=0.007), whereas the increase in AUC was modest and not statistically significant. Conclusion: Elevated RCII was independently associated with an increased risk of CI-AKI in patients with STEMI undergoing PCI. RCII may serve as a simple and readily available biomarker to assist in risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.